The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global medical aesthetics market reached a value of US$ 13.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 24.53 Billion by 2027, exhibiting a CAGR of 9.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Medical aesthetics involves the usage of different medical procedures, such as facial injectables, photo facials, body contouring and cellulite treatment, laser hair removal, and cosmetic surgery. It is performed by qualified doctors to repair the skin and improve the cosmetic appearance of an individual. As it is quick, safe, effective, minimally invasive, requires little downtime, minimizes aging, enhances the natural look, and offers a long-lasting impact, medical aesthetics finds extensive applications in hospitals, clinics, medical spas, and beauty centers worldwide.
At present, there is a rise in the utilization of minimally invasive and non-invasive aesthetic procedures across the globe. This, along with the rising awareness among individuals about medical aesthetics, represents one of the key factors driving the market. Moreover, the wide availability of technologically advanced and user-friendly products is bolstering the growth of the market. In addition, there is an increase in the number of doctors and surgeons providing safe and effective medical aesthetic treatments around the world. This, coupled with various advantages over traditional surgical procedures, such as less pain, reduced scarring, and quicker recovery, is positively influencing the market. Besides this, the growing trend of medical tourism due to the high quality of service and health insurance portability is catalyzing the demand for medical aesthetics. Additionally, the growing prevalence of congenital anomalies of the face is offering lucrative growth opportunities to industry players. These players are also extensively investing in research and development (R&D) activities to propel their overall sales and profitability. Apart from this, governments of several countries are undertaking initiatives to promote awareness programs, which is escalating the demand for medical aesthetics.
IMARC Group provides an analysis of the key trends in each sub-segment of the global medical aesthetics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being A.R.C. Laser Gmbh, AbbVie Inc., Alma Lasers Ltd., Bausch Health Companies Inc., Cutera Inc., Cynosure, El.En. S.p.A., Fotona d.o.o., Johnson & Johnson, Lutronic, Merz Pharma GmbH & Co. KGaA and Venus Concept.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||A.R.C. Laser Gmbh, AbbVie Inc., Alma Lasers Ltd., Bausch Health Companies Inc., Cutera Inc., Cynosure, El.En. S.p.A., Fotona d.o.o., Johnson & Johnson, Lutronic, Merz Pharma GmbH & Co. KGaA and Venus Concept.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global medical aesthetics market was valued at US$ 13.9 Billion in 2021.
We expect the global medical aesthetics market to exhibit a CAGR of 9.60% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective cosmetic surgeries to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for medical aesthetics.
The rising consumer awareness towards numerous benefits of medical aesthetics over traditional surgical procedures, such as less pain, reduced scarring, and quicker recovery, is primarily driving the global medical aesthetics market.
Based on the product, the global medical aesthetics market can be categorized into devices and aesthetic implants. Currently, aesthetic implants account for the majority of the total market share.
Based on the application, the global medical aesthetics market has been segregated into surgical and non-surgical, where surgical currently holds the largest market share.
Based on the end user, the global medical aesthetics market can be bifurcated into hospitals and clinics and medical spas and beauty centers. Currently, hospitals and clinics exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global medical aesthetics market include A.R.C. Laser Gmbh, AbbVie Inc., Alma Lasers Ltd., Bausch Health Companies Inc., Cutera Inc., Cynosure, El.En. S.p.A., Fotona d.o.o., Johnson & Johnson, Lutronic, Merz Pharma GmbH & Co. KGaA, and Venus Concept.
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at